Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease
Abstract
Plasma homovanillic acid (HVA), but not plasma 3-methoxy-4- hydroxyphenylglycol (MHPG), was substantially increased in 4 patients undergoing hemodialysis, 3 patients with chronic renal failure, and 3 patients receiving carbidopa/levodopa for Parkinson's disease. These conditions should be considered in psychiatric research involving plasma HVA.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).